Skip to main content

IFD Rollover

This study enables continued access to Rilpivirine (RPV), for the evaluation of the long-term safety and tolerability of RPV in combination with other optimized background ARVs, in HIV-infected children aged 2years -<12years who were virally suppressed at enrolment.

Close Menu